Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Daratumumab in Combination With Thalidomide and Dexamethasone in Relapse and / or Refractory Myeloma

NCT03143036 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03143036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03143036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Daratumumab in Combination With Thalidomide and Dexamethasone in Relapse and / or Refractory Myeloma
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2018
Completion date
July 1, 2022
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapse and / or refractory myeloma